Exact Sciences CorporationExact Sciences CorporationExact Sciences Corporation

Exact Sciences Corporation

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪9.98 B‬USD
−1.17USD
‪−204.15 M‬USD
‪2.50 B‬USD
‪182.38 M‬
Beta (1Y)
−0.38
Employees (FY)
‪6.6 K‬
Change (1Y)
+200 +3.13%
Revenue / Employee (1Y)
‪378.75 K‬USD
Net income / Employee (1Y)
‪−30.93 K‬USD

About Exact Sciences Corporation


CEO
Kevin T. Conroy
Headquarters
Madison
Founded
1995
FIGI
BBG000CWL0F5
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
EXAS4586328
Exact Sciences Corporation 1.0% 15-JAN-2025
Yield to maturity
5.83%
Maturity date
Jan 15, 2025
EXAS4957195
Exact Sciences Corporation 0.375% 01-MAR-2028
Yield to maturity
5.32%
Maturity date
Mar 1, 2028
EXAS4806408
Exact Sciences Corporation 0.375% 15-MAR-2027
Yield to maturity
4.68%
Maturity date
Mar 15, 2027
EXAS5793007
Exact Sciences Corporation 1.75% 15-APR-2031
Yield to maturity
3.80%
Maturity date
Apr 15, 2031
EXAS5549793
Exact Sciences Corporation 2.0% 01-MAR-2030
Yield to maturity
2.65%
Maturity date
Mar 1, 2030

Explore more bonds 

Frequently Asked Questions


The current price of EXAS is 52.70 USD — it has decreased by −2.26% in the past 24 hours. Watch Exact Sciences Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Exact Sciences Corporation stocks are traded under the ticker EXAS.
EXAS stock has risen by 4.90% compared to the previous week, the month change is a −25.83% fall, over the last year Exact Sciences Corporation has showed a −21.50% decrease.
We've gathered analysts' opinions on Exact Sciences Corporation future price: according to them, EXAS price has a max estimate of 85.00 USD and a min estimate of 60.00 USD. Watch EXAS chart and read a more detailed Exact Sciences Corporation stock forecast: see what analysts think of Exact Sciences Corporation and suggest that you do with its stocks.
EXAS reached its all-time high on Jan 25, 2021 with the price of 159.54 USD, and its all-time low was 0.22 USD and was reached on Nov 21, 2008. View more price dynamics on EXAS chart.
See other stocks reaching their highest and lowest prices.
EXAS stock is 5.18% volatile and has beta coefficient of −0.38. Track Exact Sciences Corporation stock price on the chart and check out the list of the most volatile stocks — is Exact Sciences Corporation there?
Today Exact Sciences Corporation has the market capitalization of ‪9.75 B‬, it has increased by 6.29% over the last week.
Yes, you can track Exact Sciences Corporation financials in yearly and quarterly reports right on TradingView.
Exact Sciences Corporation is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
EXAS earnings for the last quarter are −0.21 USD per share, whereas the estimation was −0.20 USD resulting in a −7.20% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Exact Sciences Corporation earnings.
Exact Sciences Corporation revenue for the last quarter amounts to ‪708.65 M‬ USD, despite the estimated figure of ‪716.80 M‬ USD. In the next quarter, revenue is expected to reach ‪694.91 M‬ USD.
EXAS net income for the last quarter is ‪−38.24 M‬ USD, while the quarter before that showed ‪−15.81 M‬ USD of net income which accounts for −141.88% change. Track more Exact Sciences Corporation financial stats to get the full picture.
No, EXAS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has ‪6.60 K‬ employees. See our rating of the largest employees — is Exact Sciences Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exact Sciences Corporation EBITDA is ‪−21.95 M‬ USD, and current EBITDA margin is −3.05%. See more stats in Exact Sciences Corporation financial statements.
Like other stocks, EXAS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exact Sciences Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Exact Sciences Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Exact Sciences Corporation stock shows the sell signal. See more of Exact Sciences Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.